Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate

@article{Henriksson1988CardiovascularFO,
  title={Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate},
  author={P. Henriksson and A. Eriksson and R. Stege and L. Collste and {\AA}. Pousette and B. V. VON Schoultz and K. Carlstr{\"o}m},
  journal={The Prostate},
  year={1988},
  volume={13}
}
Thirty‐eight patients with cancer of the prostate were treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections–160 mg, 240 mg, and 320 mg—in this nonrandomized study. In contrast to studies with oral estrogens, there have been no cardiovascular complications at a mean follow‐up of 12.9 ± 0.7 months (SEM). Twenty‐nine of the 38 patients (76%) have responded to therapy. 
Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer.
Estrogen in Patients with Prostatic Cancer
...
1
2
3
...

References

SHOWING 1-8 OF 8 REFERENCES
Carcinoma of the prostate: treatment comparisons.